Company facts
- Headquarters
- Wilmington, Massachusetts
- Most recent report
- 10-Q, filed Aug 5, 2026
- Filings on record
- 1,004+ filings
- On EDGAR
- CIK 1100682
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 42
News 8 of 112
Prospectuses and Registrations 7
- S-8 Registration statement for an employee plan May 7, 2026
- S-3ASR Automatic shelf registration May 9, 2024
- S-3ASR Automatic shelf registration May 4, 2021
- S-8 Registration statement for an employee plan May 21, 2020
- S-8 Registration statement for an employee plan May 18, 2018
- S-3ASR Automatic shelf registration May 9, 2018
- S-8 Registration statement for an employee plan Jul 13, 2016
Proxies 8 of 14
- DEF 14A Proxy statement for a shareholder vote Mar 31, 2026
- DEF 14A Proxy statement for a shareholder vote Apr 2, 2025
- DEFA14A Extra proxy material Apr 24, 2024
- DEF 14A Proxy statement for a shareholder vote Mar 29, 2024
- DEFA14A Extra proxy material May 1, 2023
- DEF 14A Proxy statement for a shareholder vote Mar 30, 2023
- DEFA14A Extra proxy material Apr 25, 2022
- DEF 14A Proxy statement for a shareholder vote Mar 30, 2022
Ownership 8 of 808
- SCHEDULE 13G/A Large holder reported a passive stake, amended Sep 8, 2026
- 4 Insider reported a trade Aug 27, 2026
- 144 Notice of a proposed sale of restricted stock Aug 25, 2026
- 4 Insider reported a trade Aug 20, 2026
- 4 Insider reported a trade Aug 20, 2026
- 4 Insider reported a trade Aug 20, 2026
- 144 Notice of a proposed sale of restricted stock Aug 19, 2026
- 144 Notice of a proposed sale of restricted stock Aug 18, 2026
Other 8 of 21
- SD Conflict minerals disclosure May 11, 2026
- ARS Annual report sent to shareholders Mar 31, 2026
- SD Conflict minerals disclosure May 16, 2025
- ARS Annual report sent to shareholders Apr 2, 2025
- SD Conflict minerals disclosure May 29, 2024
- ARS Annual report sent to shareholders Mar 29, 2024
- UPLOAD Comment letter from SEC staff Dec 5, 2023
- CORRESP Reply to SEC staff Nov 21, 2023
What to read: Jun 2026 10-Q
SECSift found 3 of 11 sections worth reading, with 0 positive, 2 notable, and 6 negative flags.
Financial Statements (Item 1)
Core financials with loss, large divestiture charges, and debt increase.NotableManagement's Discussion (Item 2)
Revenue down, net loss, debt spike, cash flow drop, and large divestiture loss all need attention.Negative- Charles River may have to fund up to $45M of future EBITDA losses and capex for divested CDMO/Cell Solutions businesses.
- Revenue down 2.7% to $1.0B in Q2 2026; all three segments decreased, led by Manufacturing.
- Net loss of $1.5M in Q2 2026, swinging from $52.3M net income a year ago, driven by divestiture loss.
- Operating cash flow fell 41% in H1 2026 to $220.8M from $376.3M, due to higher bonus and deal payments.
Legal Proceedings (Item 1)
Securities fraud lawsuit revived on appeal; case back in district court.
What changed: Jun 2026 vs. Mar 2026
About 16% of CRL's Jun 2026 10-Q is new information. 46 paragraphs were added, 151 changed, and 44 removed. Below are the most important lines SECSift identified.
New
Changed
Removed
Everything here comes from Charles River Laboratories International, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour. SECSift analysis was completed on Aug 19, 2026, from the 10-Q for Jun 2026.